Kiniksa Pharmaceuticals International, plc has reported significant share transactions involving its Chief Accounting Officer, Michael R. Megna, according to a recent SEC filing. The transactions, which took place on November 9, 2026, are noteworthy as they reflect ongoing executive activity within the company.

This update is important for Kiniksa Pharmaceuticals, a company focused on pharmaceutical preparations, as it highlights the fluidity of share ownership among its executives. Such movements can influence investor perceptions and market dynamics.

Background

Kiniksa Pharmaceuticals International, plc, with a CIK of 0001730430, operates under the SIC code 2834, which corresponds to Pharmaceutical Preparations. The company trades on the Nasdaq under the ticker symbol KNSA. It is categorized as a large accelerated filer and has been active in the market with several recent filings.

What the Filing Says

The SEC filing reveals that Megna acquired 11,280 shares of Class A Ordinary Shares at a price of $17.76 per share. Additionally, he sold the same number of shares at a weighted average price of $98.54. Following these transactions, he now owns a total of 23,977 shares directly.

Impact

These transactions may affect Kiniksa Pharmaceuticals' investor relations and market perception. The activities of executives, especially in the pharmaceutical sector, can signal confidence or concerns about the company’s future. Investors and analysts will likely scrutinize such movements closely.

What's Next

The filing does not say what happens next.